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Abstract
A facile method for quantifying the concentration of the powerful and widely available
hallucinogen salvinorin A (a selective kappa opioid agonist) from non-human primate
cerebrospinal fluid (CSF) and human plasma has been developed using liquid chromatography-
tandem mass spectrometry (LC-MS/MS) in positive electrospray ionization (ESI) mode. With
CSF solid phase extraction can be avoided completely by simply diluting each sample to 10 % (v/
v) acetonitrile, 1 % (v/v) formic acid and injecting under high aqueous conditions for analyte
focusing. Extensive plasma sample preparation was investigated including protein precipitation,
SPE column selection, and plasma particulate removal. Human plasma samples were centrifuged
at 21,000 × gravity for 4 minutes to obtain clear particulate-free plasma, from which 300 μl was
spiked with internal standard and loaded onto a C18 SPE column with a 100 mg mL−1 loading
capacity. Guard columns (C18, hand packed 1 mm × 20 mm) were exchanged after backpressure
increased above 4600psi, about 250 injections. A shallow acetonitrile/water gradient was used, 29
to 33% CH3CN over 8 minutes to elute salvinorin A. Reduction of chemical noise was achieved
using tandem mass spectrometry with multiple reaction monitoring while sensitivity increases
were observed using a 50 μL injection volume onto a small bore analytical column (C18, 1 mm ID
× 50 mm) thus increasing peak concentration. Limits of quantification were found to be 0.0125 ng
mL−1 (CSF) and 0.05 ng mL−1 (plasma) with interday precision and accuracy below 1.7 % and
9.42 % (CSF) and 3.47 % and 12.37 % (plasma) respectively. This method was used to determine
the concentration of salvinorin A from an in vivo Rhesus monkey study and a trial of healthy
human research participants, using behaviorally active doses.
1 Introduction
The hallucinogenic mint (Lamiaceae family) plant Salvia divinorum, has been used for
centuries by the indigenous people of Oaxaca, Mexico1–3. Mazatec shamans have used S.
divinoum for its hallucinogenic properties in divination ceremonies as well as ethnomedical
practices. Salvinorin A1, the active component of S. divinorum, is a nonnitrogenous
neoclerodane diterpene which is a selective and highly efficacious κ-opioid agonist
hallucinogen4, 5. Unlike classic hallucinogens such as psilocybin, mescaline and LSD,
salvinorin A effects are not meditated through the 5-HT2A serotonin receptor4–7. When the
leaves of S. divinorum are smoked, or isolated salvinorin A is vaporized, resulting in a fast
onset and often very strong psychoactive effects, which decline rapidly over 20 – 30
minutes2, 3, 8. The smoking of S. divinorum leaves and their extracts has become popular
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within certain cultures around the world. In the US S divinorum leaves and extracts are
easily accessible through internet sales and local “head shops”. Since the mid-1990s the use
and availability of S. divinorum has increased2, 3, 9, although use appears to have recently
stabilized at non-trivial levels, with lifetime use among teens remaining approximately
stable at nearly 6% for the last 3 years (2009–2011)10. With prevalent salvinorin A use and
yearly increases in salvinorin A regulation throughout the US and worldwide11 the
investigation of its pharmacokinetic profile has become an area of interest in clinical and
translational settings8, 12. Recent studies have investigated the in vivo pharmacokinetic
parameters of salvinorin A using mice13, non-human primates12, 14, 15, and humans8
however these studies have been limited by either the biological fluid tested or method
sensitivity to quantify salvinorin A. Like many CNS active agents, profiling
pharmacokinetic parameters involves sampling of the blood plasma or (when available)
cerebrospinal fluid to quantify how much agent is in circulation, or present in central tissues,
respectively (with the caveat that CSF levels are not identical to CNS tissue levels16).
Repeated assessment over time permits quantification of an agent, either in CSF or plasma
levels and allows for comparison to the time course of behavioral effects16. While a method
has been developed for the quantification of salvinorin A in plasma17, 18, it only presents
results from salvinorin A spiked into pooled plasma. In our hands, we found a marked
difference between plasma samples obtained from individual participants and plasma that
has been pooled and processed by commercial vendors. The individual donor samples
required a robust plasma work up to quantitate salvinorin A and note individual donor
samples are probably more challenging than pooled. Herein we describe a method for the
detection of salvinorin A from CSF that is both sensitive and requires modest sample




Experimental studies in non-human primates were approved by the Rockefeller University
Animal Care and Use Committee16. Experimental studies in humans were approved by the
Institutional Review Board of the Johns Hopkins University School of Medicine. Human
participants gave their informed consent before participation in trials.
2.2 Chemicals and solutions
Salvinorin A was extracted from the dried leaves of S. divinorum according to previously
described methods19, 20. All solvents used were of HPLC quality and were purchased from
Sigma-Aldrich chemical company. Deuterium labeled salvinorin A, (3) was prepared from
salvinorin A as previously described20. Preparation of internal standard, (4), was performed
according to recent semisynthetic procedures developed starting from salvinorin A21. All
stock solutions were prepared at a concentration of 1.0 mg mL−1 in acetonitrile and stored at
2 °C. All stock solutions were remade after a two week period to prevent changes in
concentration or degradation of the analyte. SPE column washing solution contained 10 %
methanol and 90 % Millipore H2O (v/v). SPE column elution solution contained 25 %
acetonitrile and 75 % dichloromethane (v/v). Reconstitution solution contained 35 %
acetonitrile, 64 % Millipore H2O, and 1 % formic acid (v/v/v).
2.3 Synthesis of plasma internal standard
Internal standard 5 was prepared by first converting salvinorin A to salvinorin B (via
previously described methods20), which was then purified by flash column chromatography
(0.5 % MeOH/99.5 % DCM). Prior experience with ‘proton’ contamination dictated a
method in which all possible sources of protons were exchanged prior to derivatization and
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workup. A 10 mL round bottom flask was then washed with D2O/soap and rinsed with D2O
before being placed in an oven to dry. Once dry the flask was quickly capped and injected
with 5.0ml of CDCl3, without letting the glass cool, then flushed with argon until cool. Once
cooled pure salvinorin B (50 mg, 0.128 mmol) and 4-(dimethylamino)pyridine (6 mg, 0.05
mmol) were added to the flask, which was again flushed with argon. Once dissolved, to the
solution was added acetic anhydride – 13C4, d6 99 % 13C, 97 % D (55 μL, 0.64 mmol) and
allowed to stir at room temperature. Although the reaction appeared to be finished by TLC
after only 3 hours it was allowed to stir for 7 hours to assure the reaction had reached
complete conversion to the labeled analogue 5. MeOD (2 mL) was then added to the
reaction flask and the solution concentrated under reduced pressure. CDCl3 (6 mL) was
added to the remaining residue before washing with DCl (35 wt. %) in D2O (4 × 4mL). The
remaining organic layer was then concentrated under reduced pressure to afford a white
solid (52.8 mg, 0.122 mmol) in 95.3% yield, which was used without further purification.
Upon analysis by HPLC the sample was determined to be at least 97.44% pure with no
traces of salvinorin B in the chromatogram. Analysis by LC/MS/MS the isotopic purity of 5
to 1 was determined to be >99.99%.
2.4 Preparation of plasma blanks
Calibration standards were made by serial diluting stock solutions of 1 and 5 which were
added to pooled human plasma containing acid-citrate-dextrose (ACD) as an anticoagulant.
Citric acid, sodium citrate, and dextrose function similar to ethylenediaminetetraacetic acid
(EDTA) by chelating Ca2+ ions to block proper function of the coagulation cascade making
the addition of other anticoagulants unnecessary. Specifically, to a 1.5 mL microcentrifuge
tube was added 350 μL of plasma, 100 μL of 5 from a 10 ng mL−1 solution, and 100 μL
from an individual dilution of 1. Samples were then briefly vortexed before submitting to
solid phase extraction. Final standards consisted of 350 μL samples in reconstitution
solution containing (1a) at 0.25, 1.0, 5.0, 10, 50 ng mL−1, and 1b at 2.86 ng mL−1.
2.5 Cerebrospinal fluid blanks
Calibration standards were made by serial diluting stock solutions of 1 and 4 which was
added to sufficient artificial cerebrospinal fluid (ACSF). ACSF consisted of a 126 mM
NaCl, 2.5 mM KCl, 20 mM HEPES, 1.2 mM NaH2PO4, 25 mM NaHCO3, 2.4 mM CaCl2,
and 1.2 mM MgCl solution at pH 7.4.22–24 Final standards consisted of 1.0 mL samples in
ACSF containing (1) at 0.125, 0.25, 1.0, 5.0, 10, 50 ng mL−1, internal standard (4) at 2.86 ng
mL−1, 10 % (v/v) acetonitrile, and 1.0 % formic acid (v/v).
2.6 Preparation of human plasma samples
Seven participants inhaled vaporized doses of salvinorin A of either 18.0 (2 participant) or
21 μg kg−1 (5 participants). For each participant 12 blood samples were collected up to 90
minutes post inhalation. Samples were centrifuged in a refrigerated environment to obtain
plasma. Plasma samples (stored at − 80 °C) were thawed on ice until free of any frozen
particulates. Plasma samples were then prepared by adding 400 μL of plasma to a 1.5 mL
microcentrifuge tube which was then centrifuged at 21000 × g for 4 minutes. The
centrifugation split the plasma sample into three layers, particulates on bottom, clear plasma
in the middle, and a fatty layer on top. From these layers 350 μL was carefully pipetted out
of the middle layer. The 350 μL was then transferred to a new 1.5 mL microcentrifuge tube
to which was added 100 μL of 5 from a 10 ng mL−1 solution in reconstitution solution. The
resulting solution was then vortexed and subjected to solid phase extraction.
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2.7 Preparation of rhesus monkey CSF samples
CSF samples containing salvinorin A were stored at − 80 °C until shortly before processing.
Samples were thawed in an ice-bath until they were free flowing and free of ice crystals.
Once thawed 300 μL of CSF sample was transferred to a high recovery sample vial and
diluted to a total volume of 350 μL while containing 10 % acetonitrile, 1.0 % formic acid,
and 1.0 ng of internal standard (4). Samples were then analyzed using multiple reaction
monitoring (mrm) on a LC-MS/MS system.
2.8 Soild Phase Extraction
Strata C18-E 55 micron, 70 Å SPE cartridges (Phenomenex, Torrance, CA) were used
during preparation of both standard and human samples. A 12-Position SPE vacuum
manifold from Phenomenex was used with vacuum pressure between 1 and 10 inches of Hg,
depending on consistency of plasma, to maintain a flow rate of approximately 1 mL min−1.
SPE columns were conditioned by washing sequentially with 3 mL of methanol and 3 mL of
Millipore H2O. Plasma samples were then loaded onto the column and rinsed with 3 mL of
washing solution before being dried under gentle vacuum for 5 minutes. Salvinorin A was
then extracted off the columns into 2 dram vials using 2 mL of eluting solution and
evaporated to dryness under a gentle stream of nitrogen gas at room temperature. Extracts
were then reconstituted into 350 μL of mobile phase and transferred to a total recovery
autosample vial.
2.9 Instrumentation
Samples were injected on a Waters Acquity UPLC (Waters corp Milford, MA), however,
separations were performed on conventional HPLC media at traditional flow rates. Column
effluent was into a Micromass Quattro Ultima (Micromass LTD Manchester, UK) triple
quadrupole mass spectrometer with an electrospray source via a divert valve that shunts the
injection front to waste. A Micro-Tech Scientific 1 mm ID × 5cm Zorbax C18 300 Å 3.5
micron column preceded by a 2.0 cm × 1 mm ID guard column was used to separate
salvinorin A from internal standard and impurities. The HPLC solvent gradient is outlined in
Table 1. Data was collected and processed using MassLynx version 4.1 (Waters Inc.).
Instrumental parameters are summarized in Table 2. Guard columns were hand packed using
1 mm “kits” (upchurch/idex P/N C-128).
3 Results and Discussion
While previously it has been shown that salvinorin A (1) can be detected in CSF following
i.v. administration, these procedures employed lengthy SPE procedures before the samples
were ready for instrumental analysis and were limited by the use of MS1 only (no MS/MS)
scanning18. By removing any SPE procedures, the turnover time from sample collection to
processed data was greatly reduced taking only about one minute per sample to prepare. We
had hoped a similar procedure could be followed with plasma samples, initial attempts at
reproducing previously published methods18 resulted in repeated clogging of the 30 mg
mL−1 SPE cartridges. While commercially processed plasma was void of any sample
processing issues, it was immediately apparent there was a broad variability in the
propensity to clog an SPE column with plasma across individual participants as well as
individual samples within a participant sample set. Switching to a higher loading capacity
column did appear to slightly remedy the issue, although it did not completely prevent the
columns from becoming clogged (Table 3). Due to the desire to maintain sensitivity, amount
of plasma per injection, and the concern that loading SPE columns beyond 100 mg mL−1
would require a significant increase in elution volume which would make the reconstitution
step less consistent, further plasma pretreatment was explored using the most successful
Strata C18-E columns.
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Plasma sample pretreatment was investigated to avoid SPE columns from becoming
clogged. Solvent protein precipitation with either cold ethanol or cold acetonitrile was
pursued, however, the SPE columns were still obstructed. We next attempted to removal of
particulates via prolonged centrifugation. Upon centrifugation for several minutes it was
noticed that samples separated into a pellet, clear plasma, and a third fatty lipid-like layer.
Upon loading the clear plasma, middle layer, onto an SPE cartridge it was found that it
easily passed through the column and allowed solvent to freely flow through the column
with minimal vacuum pressure thus making centrifugation our standard plasma pretreatment
preparation method.
Standard curve samples were prepared from ACSF due to the limited supply of natural CSF.
Removing the SPE workup from the CSF sample and residual impurities in plasma samples
however did slowly clog the HPLC guard column and raise the pressure within the
instrument. The pressure increase over injection cycles was remedied by changing the guard
column after the pressure had increased to over 4600 psi, but never until all injections had
been completed from a single participant series. Usually 70 to 400 injections, depending on
sample quality, could be made before the pressure warranted repacking of the guard column.
The pressure limit “error” feature in the Acquity software stopped injections as needed.
After reproducible sample preparation for both CSF and plasma was obtained we next
focused on selecting an appropriate internal standard. A previous method using an APCI
source and SIM acquisition or MS scans only (e.g. no MS/MS) successfully used 3 as an
internal standard18. However when converting to MS/MS the increase in sensitivity revealed
a slight impurity of 1 detected within the deuterated sample 3, observed as cross-talk
between the mrm channels with pure internal standard injections. Presumably the small
impurity comes from deuteron-proton exchange with the glassware during synthesis of 3.
The previously published synthetic procedure20 was followed three times by two chemists
each time using freshly prepared salvinorin A, with special attention paid to anhydrous
technique to reduce the number of exchangeable protons in the system. However in each
case, there was found approximately 2–3% of (433u)-salvinorin A, 1, mixed into the
deuterium labeled (435u)-salvinorin A, 3. In order to avoid the need for additional
mathematical manipulation during data processing to account for this impurity, internal
standard 4 was used for processing CSF samples because of its structural similarity, column
retention, and +28 mass units in relation to 1. A successful of a “pure” +5 mass analogue of
salvinorin A used completely deuterated solvents and glass ware washes to help eliminate
deuteron-proton exchange. In blank rhesus monkey cerebrospinal fluid, collected in the
absence of salvinorin A, no interference was found on the chemical transitions monitored for
1 and 4. After altering the synthetic method previously used for the synthesis of (433u)-
salvinorin A it was found that with extensive washing of glassware with D2O and
performing the synthesis in a “perdeuterium” environment the cross-talk between channels
was eliminated by > 99.99% as observed in the MS. The synthetically and isotopically pure
(438u)-salvinorin A was used during the processing of human plasma samples.
It has been previously shown that salvinorin A can be metabolized to salvinorin B ex vivo by
both human18 or rat plasma13, however formation of salvinorin B, 2, was not observed
during the processing of human samples. As the main purpose of this study was the
quantification of 1 rather than 2 we chose not to pursue a lower limit of detection and only
monitored for the appearance of 2, which would indicate salvinorin B is an in vivo
metabolite of salvinorin A. Linear detection of 2 above 1.0 ng mL−1 was possible, however
this required the monitoring of three chemical transitions of 2 391/251, 391/145, and
391/259. It should be noted however that the metabolism of 1 to 2 has been shown to be
slowed significantly at lower temperatures13. As the autosampler temperature was set to 4
°C and the time from SPE processing to placement within the autosampler was kept to a
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minimum, there may not have been sufficient time to produce detectable amounts of 2 due
to the fast processing and reduced temperature storage between injections. Additionally even
though significant quantities of 2 were not detected, there still remains a possibility that 2
may be conjugated to a sugar such as the glucuronide very rapidly. The CID transitions for
the detection of conjugate derivatives of 2 were not monitored.
Percent recovery was calculated from integrated peak area ratios of salvinorin A undergoing
SPE procedures versus salvinorin A injected from organic solvent. Precision was defined as
the average standard deviation from each injection for every sample in all standard curves,
calculated as the ratio of the standard deviation to the mean (81 injections for CSF, 168
injections for plasma). Accuracy was defined as the deviation of the calculated concentration
from the theoretical standard concentration for each injection for every sample in all
standard curves (81 injections for CSF, 168 injections for plasma). Precision and accuracy
were calculated using quality control points of 0.5, 2.5, and 25 ng mL−1, table 4 summarizes
statistical data compiled during sample processing. The lower limit of quantification
(LLOQ) was defined as the point where signal to noise remained ≥5:1, while the precision
and accuracy remained better than 20%, as seen in Figure 2. For CSF samples the LLOQ
was determined to be 0.0125 ng mL−1 with precision and accuracy of 5.8 % and 10.96 %
respectively. For Plasma samples the LLOQ was determined to be 0.05 ng mL−1 with
precision and accuracy of 4.7 % and 7.47 % respectively. Analyte stability remained
consistent in prepared samples for at least two weeks when frozen and stored at -20°C or 8
hrs when stored at ambient temperatures as that was the longest time duration between
injections of a prepared sample. For CSF samples analytical standards were prepared in
artificial cerebrospinal fluid due to limited access to the large volumes of authentic
cerebrospinal fluid that would be required for all the standard samples. Matrix effects were
not encountered in either plasma or CSF samples with excellent linearity observed in
respective standard curves and recoveries were near 100% comparing matrix mixed samples
to “clean” solvent standards. Chromatograms of blanks and authentic samples can be seen
for both CSF and plasma in figures 3 & 4 respectively. These chromatograms were
randomly selected and increased peak widths correlate to the end of guard column use. Time
course graphs for a full series of in vivo data points from both CSF and plasma samples can
be seen in figures 5 & 6 respectively. Here the data fit to common anecdotal profiles of
salvinorin A with a rapid onset and fast extinction of behavioral effects for non-human
primate CSF.12 Moreover, the profile observed in human participants fits the subjective
behavioral effects and drug strength ratings of participants who have used salvinorin A.8
Full data collected on the time course of salvinorin A effects in rhesus monkey CSF linked
to behavioral effects have been published16, while full data on behavioral effects of
salvinorin A in human plasma are being prepared.
Conclusions
The method described allows for the quantification of salvinorin A at behaviorally active
doses16 from cerebrospinal fluid after i.v. injection in non-human primates, and from plasma
after inhalation in humans. Plasma samples showed an order of magnitude increase in
sensitivity from prior methods, while in CSF samples SPE procedures were successfully
bypassed while increasing the level of sensitivity two orders of magnitude relative to
previously published methods14, 18. Major increases in sensitivity were derived from larger
injection volume with analyte focusing on a smaller inner diameter column thus increasing
peak concentration, while MS/MS transitions reduced chemical noise as anticipated.
However these techniques do warrant the monitoring of back pressure on the LC and guard
column, reduction in sample work-up (CSF samples) and large injection volumes onto a
smaller inner diameter column slowly obstructed the guard column and increased back
pressure due to slow clogging during sample injection. Backpressure was relieved by
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repacking of the guard column as needed depending on sample cleanliness. Synthesis and
use of new internal standards 4, 5 prevented cross talk between mrm channels and
eliminated the need for mathematical manipulation of the data due to impurities formed
from deuteron-proton exchange during chemical synthesis of 3. The method described was
successfully used during the processing of plasma samples of a human study across multiple
subjects, as well as a non-human primate study in which salvinorin A was quantified from
CSF across multiple subjects16.
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Chemical structures, exact masses and mrm transitions of salvinorin A (1), salvinorin B (2),
d3-salvinorin A (3), Internal standard for CSF samples (4), and d3, 13C2-salvinorin A (5)
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LC/MS/MS chromatogram with a signal to noise measurement for the internal standard (3)
at a concentration of 2.86 ng mL−1 (Panel A). LC/MS/MS chromatogram and signal to noise
measurement for the salvinorin A (1) at a concentration of 0.0125 ng mL−1 (Panel B).
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Representative chromatograms of CSF samples. Internal standard and analyte channels for a
baseline blank injection (Panel A). Analyte and internal standard from an authentic CSF
time course sample (Panel B).
Caspers et al. Page 11














Representative chromatograms of plasma samples. Internal standard and analyte channels
for a baseline blank injection (Panel A). Analyte and internal standard from an authentic
plasma time course sample (Panel B).
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Salvinorin A in rhesus monkey CSF after a 100ug/kg dose
Caspers et al. Page 13














Salvinorin A from human plasma after smoking a dose of 19 ug/kg.
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Table 1
Solvent gradient program used for elution during LC-MS/MS analysis25.
Time (min) Flow Rate % Solvent A† % Solvent B‡
Initial .135 99.0 1.0
1.0 .135 99.0 1.0
2.0 .135 71.0 29.0
10.0 .135 67.0 33.0
10.1 .145 5.0 95.0
11.0 .145 5.0 95.0
12.0 .130 99.0 1.0
†
 Solvent A consisted of 99.0 % H2O and 1.0 % acetonitrile
‡
 Solvent B consisted of 99.92 % acetonitrile and 0.08 % formic acid













Caspers et al. Page 16
Table 2
Set parameters of instrumentation
Parameter Set Value
Ionization Mode ES+
Injection Volume 50.00 μL
Capillary 2.81 kV
Source Temperature 100 °C
Desolvation Temperature 250 °C
Q1 & Q3 Resolution 0.8 amu, wh
Collision Cell Pressure 1.55e−3 mbar
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Table 3
SPE columns tried for the extraction of salvinorin A from human plasma.
SPE Column Loading Capacity SPE Attempts Attempts Plugged Plasma Volume
Oasis HLB 30 mg mL−1 5 5 200 μL
Strata-X 30 mg mL−1 5 5 200 μL
Strata-X-C 30 mg mL−1 5 5 200 μL
Strata-X-CW 30 mg mL−1 5 5 200 μL
Strata C8 100 mg mL−1 5 2 400 μL
Strata C18-E 100 mg mL−1 5 2 400 μL
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Table 4
Statistical data for salvinorin A from rhesus monkey CSF and human plasma
Parameter Monkey CSF Human plasma
Linearity 0.0125 – 50 ng/mL1 0.25 – 50 ng/mL3
(R2) ≥.998 0.997 – .9994
Limit of Quantification 0.0125 ng/mL 0.05 ng/mL
Precision (Interday, Intraday) CV (< 1.7 %, < 1.3 %)2 CV (< 3.47 %, < 2.85 %)5
Accuracy (Interday, Intraday) (< 9.42 %, 4.94 %)2 (< 12.37 %, 7.08 %)5
Percent Recovery 93% – 114%
1
Six-point calibration curve ran in triplicate
2
Calculated from 3 sets of 27 injections each
3
Five-point calibration curves ran in triplicate
4
Range of correlation coefficients over seven trials
5
Calculated from 7 sets of 27 injections each
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